International Journal of Biosciences | IJB | ISSN: 2220-6655 (Print), 2222-5234 (Online) http://www.innspub.net Vol. 9, No. 2, p. 16-26, 2016

RESEARCH PAPER

OPEN ACCESS

Development of recombinant cells encoding surface proteins of *Corynebacterium pseudotuberculosis* against caseous

lymphadenitis in goats

Syafiqah Adilah Shahridon¹, M. Zamri-Saad M^{*1}, Z. Zunita², M. Rozaihan³

¹Research Center for Ruminant Diseases, Universiti Putra Malaysia, Serdang, Malaysia

²Department of Veterinary Pathology and Microbiology, Universiti Putra Malaysia, Serdang, Malaysia

^sDepartment of Medicine and Surgery of Farm and Exotic Animals, Universiti Putra Malaysia, Serdang, Malaysia

Key words: Corynebacterium pseudotuberculosis, Caseous lymphadenitis, Recombinant cells, Surface proteins.

http://dx.doi.org/10.12692/ijb/9.2.16-26

Article published on August 20, 2016

Abstract

Caseous lymhadenitis is an infectious disease caused by an intracellular bacterium, Corynebacterium pseudotuberculosis. Control is via vaccination. This report describes construction of two recombinant cells; one that carried the putative surface-anchored protein, the SpaA (pET32/LIC-SP31) and the other the glyceraldehyde-3-phosphate dehydrogenase protein, the GAPDH (pET32/LIC-SP40). The recombinant cells were introduced into goats before aAntibody response by the goats and protective capacities of the recombinant cells were measured. Fifteen goats were divided into3 groups. Group 1 was injected intramuscularly with PBS, Groups 2 and 3 were injected on days 0 and 14 with 106 CFU/ml of recombinant pET32/LIC-SP31 and pET32/LIC-SP40 cells, respectively. Serum samples were collected weekly to determine the antibody levels using ELISA. Two weeks after the last vaccination, all goats were challenged subcutaneously with 109 CFU/ml of live C. pseudotuberculosis. The results revealed that goats exposed to the recombinant cells showed significantly (p<0.05) higher IgG level compared to the control that lasted for 11 weeks. Generally, the exposed groups showed similar antibody pattern although those exposed to pET32/LIC-SP40 showed insignificantly (p>0.05) higher level in the first 7 weeks than the recombinant pET32/LIC-SP31. Following challenge at week 6, abscesses were observed in the lymph nodes of all groups while C. pseudotuberculosis was successfully isolated. The recombinant cells were able to induce humoral response but failed to protect the goats against challenge by live C. pseudotuberculosis.

* Corresponding Author: M. Zamri-Saad M 🖂 mzamri@upm.edu.my

Introduction

Caseous lymphadenitis (CLA) is a chronic disease of goats and sheep that is caused by Corynebacterium pseudotuberculosis (Literak et al., 1999). It is characterized by the formation of abscesses in the superficial and internal lymph nodes and occasionally in the internal organs (Centikaya et al., 2002). The disease causes significant economic losses to goat and sheep industries due to decreased production and quality of milk and wool other than condemnation of carcass and skin in abattoirs (Simmons et al., 1998; Hoelzle et al., 2013). Vaccination has been used to reduce the spread and gradual decline the disease prevalence (Dorella et al., 2006; Fontaine and Baird, 2008). There are several types of vaccine against CLA, which include inactivated whole cells, toxoid of C. pseudotuberculosis, live and DNA vaccines (Izgur et al., 2010). However, the current commercially available vaccines are not effective in protecting against CLA (Guimarães et al., 2011).

Gram-positive bacteria lack outer membrane proteins (Desvaux *et al.*, 2006) but possess surface proteins (Schneewind and Missiakas, 2014). Cell surface of Gram-positive bacteria displays proteins that are frequently considered as virulence factors that can potentially be used for vaccine development (Desvaux *et al.*, 2006). This paper describes the construction of recombinant cells carrying surface proteins of *C. pseudotuberculosis* and reports the antibody response and protective capacity provided by these inactivated recombinant cells against caseous lymphadenitis in goats.

Materials and methods

Bacterial strain, plasmid and culture condition

Two isolates of *C. pseudotuberculosis*, UPM J1 and UPM J2 were used in this study. They were obtained from local outbreaks of caseous lymphadenitis. The isolates were cultured on 5% blood agar for 48 h at 37°C before pure colonies of *C. pseudotuberculosis* were further subcultured into 15 mL of brain heart infusion broth (Oxoid, UK) and incubated for 48 h with gentle shaking at 37°C. A non-expression host,

17 Shahridon *et al*.

the *E. coli* strains Nova-Blue Giga-Singles (Merck, Germany) and an expression host, the *E. coli* strain BL21 (DE3) (Merck, Germany) were used for cloning and expression. The expression vector, pET-32 Ek/LIC was obtained from Merck, Germany.

Preparation of the surface proteins of Corynebacterium pseudotuberculosis

Surface proteins of C. pseudotuberculosis were prepared according to Sabri et al. (2000). The bacterial isolate was grown in one litre of brain heart infusion broth (BHIB) in 250 rpm incubater shaker at 37 °C for 48 h. The bacteria cells were harvested by centrifugation at 5000 rpm for 20 min where the pellet was washed three times by centrifugation at 5000 rpm for 10 min. The pellet was resuspended in 20 ml of PBS (pH 7.2) and sonicated 3 times for 10 min on ice. The cell lysate was exposed to diethylether for 6 h before centrifuged at 6000 rpm for 30 min. The supernatant was further centrifuged at 28 000 rpm for 2 h at 4°C, the pellet was resuspended in 2 mL of 1% sodium lauryl sarcosinate (Sigma, UK) and incubated for 2 h. The suspension was centrifuged again at 28 000 rpm for 2 h at 4°C before the pellet was resuspended in 100 µl sterile PBS and stored at -20°C. The concentration of surface proteins was determined using the Qubit flourometer probes (Invitrogen, USA).

Preparation of rabbit hyper-immune serum against whole cell C. pseudotuberculosis

Hyperimmune serum against *C. pseudotuberculosis* was prepared according to Cameron and Maria (1971). *Corynebacterium pseudotuberculosis* was grown in 50 ml of brain heart infusion (BHI) broth and the concentration was determined as 10⁶ cfu/ml before resuspended in 50 ml of PBS (pH 7.2) with 0.5 % formalin and incubated overnight at 4 °C. The bacterial cells were then washed again and were mixed well with 50 ml PBS. Approximately 1 ml of the bacterial cells were mixed with 1 ml of complete Freund's oil adjuvant (Sigma, UK) and injected into rabbit subcutaneously. The injections were given on days 1, 7 and 14. The blood was collected on day 28 post-injection and the hyper-immune serum was stored in -20 °C until used.

Sodium deodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting of the surface proteins

The surface proteins of C. pseudotuberculosis were subjected to the SDS-PAGE using the Mini-Protein® II Electrophoresis Cell (BIO-RAD, USA) (Paule et al., 2004). A 12% (w/v) resolving gel solution was prepared before 4% (w/v) stacking gel solution was dispensed onto the top of the resolving gel and plastic comb was carefully inserted. Dispensing samples were prepared by mixing one part of the protein sample with one part of the SDS loading buffer (62.5 mM Tris-HCl pH 6.8, 20% glycerol, 2% SDS containing 5% (v/v) 2-mercaptoethanol). Twelve μ l of the sample and 5 µl of protein marker were loaded into the wells filled with 1x Tris-glycine running buffer (25 mM Tris; 250 mM glycine; 0.5% (w/v) SDS, pH 8.3). Voltage of 95V was applied and the gel was left running for 2 h. The gel was then stained with Coomassie blue solution (0.25% (w/v) Coomassie brilliant blue G (Sigma, UK); 45% (v/v) ethanol; 10% (v/v) acetic acid) overnight followed with staining with de-staining solution (45% (v/v) ethanol; 10% (v/v) acetic acid) for 30 min with gentle shaking. The protein bands were compared against standard of known molecular weight of protein marker.

For immunoblotting, the bands were transferred to the PVDF membrane in cold transfer buffer at 100 V, 300 mA for 2 h. Then the PVDF membrane was stained with Ponseu S for 15 min. The membrane with the transferred proteins was washed with PBST three times for 10 min each before incubated with blocking buffer for 1 h at 37°C. The membrane was washed for 10 min three times and incubated with hyperimmune serum against C. pseudotuberculosis (1:100) for 2 h at 37°C. The membrane was rinsed again with PBST three times for 10 min and goat anti-rabbit IgG (1:1000) was added, incubated for 2 h at 37°C. After incubation, the membrane was washed with PBST five times for 10 min and washed one time with TBS before being exposed with the TMB substrate solution (Promega, USA) for 2-3 min. Lastly, the membrane was washed with distilled water and dried before being used for N-terminal amino acid sequencing.

Amplification of the surface protein genes

Two set of primers were designed based on the publish sequences of *C. pseudotuberculosis* FRC41 (accession number CP002097.1) that were specific for the 31 kDa and 40 kDa genes of interest. They were LIC-SP31F (5' GAC GAC GAC GAC AAG ATG AAC AGG TTC TCT 3') and LIC-SP31R (5' GAG GAG AAG CCC GGT CTA GTT TTT AGC 3') for SP31, and LIC-SP40F (5' GAC GAC GAC AAG ATG ACG ATT CGC GTA 3') and LIC-SP40R (5' GAG GAG AAG CCC GGT TTA AAG GCG CTC 3') for SP40.

Polymerase chain reaction was carried out in 50 µl volume containing 10 µl of 5x PCRBIO reaction buffer (15Mm MgCl and 5mM dNTPs), 2 µl forward and reverse primers respectively (10 µM), 2 µl DNA template (8ng/µl), 1U PCRBIO HiFi Polymerase (2U/ µl) and 33.5 µl of sterile distilled water. The amplification of the DNA was performed using the Thermocycler (Appendorf, Germany) where the condition was set with initial denaturation step at 95°C for 1 min. The next 30 cycles were performed with 15 sec denaturation at 95°C, annealing at 66.5°C and 67°C for SP31 and SP40, respectively for 15 sec and extension at72°C for 1 min, following final extension at 72°C for 10 min and hold at 4°C. After amplification, 5 µl sample mixed with 1 µl of loading dye (Fermentas, Lithuania) was subjected to electrophoresis in a 1% agarose gel in TBE at 80 V (Bio-Rad, Germany) for 1 h and stained with GelRed nucleic acid gel stain (Biotium, USA) to detect the presence of the amplified products. Gel was visualized under an ultraviolet light transilluminator (Bio-Rad, Germany) and photograph by photography system, KODAK.

Construction and transformation of recombinant plasmid

To construct the recombinant plasmid, the gene of the surface protein was treated with T4 DNA polymerase to ensure ligation between the insert and the vector pET32 Ek/LIC. After ligation, the recombinant plasmids were transformed into cloning host, NovaBlue GigaSingle competent *E. coli* cells (Merck, Germany).

Positive clones were screened by PCR using vector specific primers, forward primer s-tagF (5'- ATG GAT AGC CCG GAT CTG GGT ACC-3') and reverse primer T7terR (5'- TTA GTG GCC CCA AGG GGT-3') (Nur-Nazifah, Sabri, & Siti-Zahrah, 2014).

Positive clones of the two recombinant plasmids were sent for DNA sequencing (1st Base, Malaysia) to confirm the presence of the cloned fragments before being used for transformation into *E. coli* BL21 (DE3) strain for expression study. The clones were screened using vector specific primers and subcultured onto Luria Bertani (LB) medium containing 50 mg/ml ampicillin overnight at 37°C with gentle shaking. The bacterial culture was mixed with 80% glycerol and stored at -80 °C until further used.

Isopropyl-beta-D-thiogalactopyranoside (IPTG) induction

The induction was performed according to the manufacturer's protocol (Novagen, USA). A positive recombinant cell colony was picked and inoculated into 3 ml of LB broth containing 50 mg/ml ampicillin overnight at 37°C. The culture was then added into 100 ml LB broth containing 50 mg/ml ampicillin. Before induction, the culture was split into 2x 50 ml culture where one mM IPTG was added into one of the 50 ml culture and the other culture was used as un-induced control. The cultures were incubated at 37 °C for 16h with shaking at 250 rpm. The expressed broths were centrifuged at 10 000 xg at 4 °C for 10 min to harvest the cells. The harvested pellets were re-suspended in 5 ml/g of Bugbuster Protein Extraction (Merck, Germany).

The supernatants that contained the soluble proteins were used for analysis and detection of the expressed protein using SDS-PAGE (Bio-Rad, USA) and Western immunoblot (Bio-Rad, USA).

Preparation of inactivated recombinant cells

Following induction, cultures of recombinant *E. coli* BL21 (DE3) expressing the surface protein genes were harvested and killed in 0.5% formalin (PBS, pH 7.4; Sigma, USA) overnight at 4 °C.

This was followed by washing three times in sterile PBS by centrifugation at 5 000 xg for 10 min at 4° C to ensure that formalin was completely removed. The inactivated recombinant cells were re-suspended in sterile PBS and the inoculums were prepared to the final concentration of 10^{6} cfu/ml using McFarland method.

Experimental design

Fifteen goats were divided into three groups. Group 1 was the unvaccinated control injected intramuscularly with PBS while Groups 2 and 3 were exposed intramuscular with 1 ml of inactivated recombinant cells prepared earlier (SP31 and SP40, respectively).

Respective booster dose was given two weeks after the first exposure. Serum sample were collected from all goats prior to and at weekly intervals post-vaccination until week 12 and subjected to ELISA to determine the antibody levels. Two weeks after booster dose, all goats were challenged with live virulent *C. pseudotuberculosis* and all surviving goats were killed at week 12. The Institutional Animal Care and Use Committee, Universiti Putra Malaysia approved the experiment (Approval No. R077/2014).

Enzyme-linked immunosorbent assay (ELISA)

Serum samples were subjected to direct enzymelinked immunosorbent assay (Paule et al., 2003). The microtitre plates were coated with 50 µl of suspension containing 106 cfu/ml of antigen diluted in citrate coating buffer and incubated overnight at 4°C. The plates were then added with 200 µl of blocking buffer and incubated at 37 °C for 1 h. After washing, 100 µl goat serum (1:500) was added and incubated at 37°C for 1 h. The plates were washed again before 100 µl rabbit anti-goat IgG-horse radish peroxidase (Nordic-MUbio, Netherland) diluted 1:8000 was added into each well and incubated for 1 h at 37°C. The plates were washed three times and 100 µl of TMB one solution substrate (Promega, USA) was added and incubated for 30 min at 37°C. Lastly, 50 µl of stopping buffer solution (2.5 M sulphuric acid) was added and the optical density was measured at 450 nm wavelengths.

Bacterial isolation and identification

Samples of lymph nodes (submandibular, prescapular, prefences, supramammary and mesenteric) and organs (lung, liver kidney and spleen) were collected and subcultured onto blood agar before incubated at 37°C for 48 h. Suspected colonies of *C. pseudotuberculosis* were confirmed by PCR according to Centikaya *et al.* (2002) using 16S rRNA primers.

Statistical analysis

Statistical analysis of the data was carried out using univariate analysis of variance (ANOVA) and Post Hoc (Turkey test) with SPSS 16.0 software (IBM, USA). The graph shows the standard error mean (SEM) for each group. The significant difference were determine when the P values <0.05.

Results

SDS-PAGE and Immunoblotting of the Surface Proteins of C. pseudotuberculosis

SDS-PAGE of the surface proteins of both strains revealed 11 bands of 140, 78, 75, 68, 64, 60, 50, 40, 36, 31 and 25 kDa. The major proteins were 31 and 40 kDa (Fig. 1). Immunoblot revealed positive reaction by protein bands 75, 40, 31 and 25 kDa (Fig. 2) with 40 and 31 kDa bands showed intense reactions. Further analyses revealed that the 31 kDa band showed 83% homology with the putative surfaceanchored protein (PSA) while the 40 kDa band showed 100% homology with the glyceraldehyde-3phosphate dehydrogenase (GAPDH) of С. pseudotuberculosis FRC41 (accession number CP002097.1).




Fig. 1. Distribution of surface proteins of *C. pseudotuberculosis* showing 11 bands with 31 and 40 kDa being the major bands. Lane 1 is UPM J1 and lane 2 is UPM J2 strains of *C. pseudotuberculosis*. Lane M is the protein marker (M).




Fig. 2. Immuno-detection of the antigenic surface proteins of *C. pseudotuberculosis* showing positive bands. Lane 1 is the UPM J1 and lane 2 is the UPM J2 strains. Lane M is the protein marker.

Development of the recombinant plasmid and expression

Amplification and DNA sequencing of the SP31 gene of *C. pseudotuberculosis* resulted in fragment size of approximately 1443 bp encoding 480 amino acids (Fig. 3) whereas SP40 revealed fragment size of approximately 996 bp encoding 331 amino acids (Fig. 4).

	10	20	80	40	60	60	70	80	90	100
sequenced	лтоалслосссла		IATGACGACG		CAGOTTCTCT	TOCOCTACOCK	CTCTOTAAC	TTTTOCTOCA	TTOTTOTT	
published	H D B P I	PLOT	DDD	ATGAAG	CAOOTTOTOT	TOCOCTACOCO	CTCTOTAAC	TTTTOCTOCA	TTOTTOOTT	FOTCTC 61
				MH	RYS	CATI	A D V T	FAA	IVGI	- a
	TTOGACTCOOCOO	120	130	140	160	140	170	100	190	200
sequenced	TTOGACTCOOCOO	OOCTCCOOCAOT	COTTOCCCA	GACATTCTT	TAOCTOCTO	CCOTOAAAOC/	AACATTGAT	TTTGAAAGAA	AGOCTCCCT	CACTCT 200
published	TTGGACTCGGCGGG	OOCTCCOOCAOT	COTTOCCCA	OGACATTCTT/	TAOCTOCTCO	CCOTGAAAAC/	LAACATTGAT	TTTGAAAAGAA	MOOCTCCCT	CACTOT 161
	LGLGG	APAV	V A Q	DIL	IAAI	P V K A	HID	TERI	K G B L	TL
	210	220	230	240	280	240	270	280	290	300
sequenced	TTATAAGAAAAGC	00C0C00AATC0	DOTGAOCAT	OCAACTOOTC/	ACCTAATOGA	GAATOTTCCTC	MAAAGCCTT	TAAA000C000	JAAATTTAAAG	CTACA 300
published	TTATAAGAAAAOCO	OOCOCOGAATCO	OGTGAOCAT	OCAACTOOTC/	CCTAATOGA	GAATOTTCCTC	BAAAAGCCTT	TAAATOOCOT	AAATTTAAAA	PCTACA 261
	Y K K H	O A E S	OEH	ATOI	LME	H. V. P.	OKP	LHQV	K F K	A T
	310	320	330	340	350	340	370	380	390	400
sequenced	R I N V	ATCTTAAAACAG	ATGATTOOC	CAAAATTTCCT	AAAAATOCO	GAAGACGCGA/	AAATAAACT	TACGACTOTA	ACCTATGAAC	AAACTA 400
published	AAAATCAATGTTG	ATCTTAAAACAG	ATGATTOOO	CAAAATTTCCT	AAAAATOCTO	annantocan/	MAATAAACT	TACGACTOTA	ACCTATGAAC	AAACTA 361
	K I N V I	DLKT	DDW	V K S. D	K II A	E D A I	C N K L	TTV	TYRG	2 7
	410 COACTOOTOAAOO	420	450	440	480	440	470	480	490	800
sequenced	салстооталлоо	V A K	TOGAGATTT	CCCACTOOOT	TTTATCTTO	roanoananc/	AAAOOCTCCT	AAAGGOGTAG	annoodoc	COULT SOO
published	COACTOOTGAAGO	OOTTOCAAAOTT	TOGAGATTT	OCCACTOOOTO	TTTATCTTO	TOGAGGAGACA	AGAGGCTCCT	GAAGGOGTAG	RAAAAOOOOC/	ACCOTT 461
	TTOEG	VARI	O D L	N F O	P A F	VEET	E A P	E G V	KOA	p p
	810	520	\$30	540	650	840	670	500	890	#00
sequenced	TATAOTTICAATT	CCTATOOTAAOC	OCTOCGAOC	AATTCTTOGA	ATTACQAAAT/	AGTTOCOTATO	CAAAAATT	COGAAACTAA	OTCOAAAAA	CAGTO 600
published	TATAOTTTCAATT	CCTATOOTAAOC	OCTOCOAOC.	AATTCTTOGAJ	TTACGAAAT	AGTTOCOTATO	CAAAAATT	COGALACTAA	AOTCOAAAAA	CAOTO 561
	IVBI	PNVS	A A B	N. B. N. J	XEX	V A X.	P. K. B. J	S & T &	VER	a v
	410	620	630	640	650	640	670	680	690	700
sequenced	K D A D	AGAATATTCAAG	ATCTTTACC	TCTATACOAT1	ACTOCAAAT	OCTCCGAATT1	TAAAGATCC	AAAAAAATTA/	ACTAAOTTTA!	TTTTCC 700
published	AAAGATOCTGATA	AGAATATTCAAG	ATCTTTACC	TCTATACQATT	ACTOCAGAT	OCTOCOAATTI	TAAAGATCC	AAAGAAGTTA	ACTAAOTTTA	TTTTCT 661
	K D A D I	KNIQ	DLY	LYTI	TAD	APNI	K D P	KKL	TRF	I F
		720	730	740	760	740	770	780	790	800
sequenced	P H R L D	TGATCGACTGOG	AAACCCAAA	OOCTACAGAAG	TTAAAOCCO	OTGATOGAACT	CTAOCCGAO	OOTGACTTCA	TGAGTCTTT	TOGTGA 800
published	CAGATAAACTTGA	TOATCOACTOOA	AAATCOGAA	OOCTACAGAAG	TAAAAOCCO	OTGATOTAACT	CTAOCCOAO	OOTGACTTCA	TOAOTCTTT	TOTTOA 761
	SDKLD	DRLI	прк	ATE	VKA	D V T	LAE	0 0		V D
	810	820	830	840	850	860	870	880	890	604
sequenced	G L Y R	OTTGAAATAAOT	GAAAAA000	CTTCCAAAAO	100CATCC00	ogvayageee	TTTTTGACCT	TTAATOTCOC'	COTAAAGAA	TCOGA 900
published	TOOOCTCTATAAA	OTTGAGATAAOT	GAAAAAGGG	CTTCTAAAAO	TOOCATCTOOK	OGTGAAOGTCI	CTTTGACCT	TTAATOTCOC	COTAAAAAAA	STCOGA 061
	0 0 3 4	Y E 4 0	E K O	1 1 K 1		Y . RY	1 1 1	C. 11. 12 - 0	A A L	v u
	910	920	990	940	960	940	970	980	990	1000
sequenced	N S V E	TCOTTAACTCTC	CTGATOTTA	TTTTTAATAAG	CCAAACACT	GAOGAAGACAT	AACACAGAAA	GACAAACGAAA	CTAAAACCT/	ATCATG 1000
published	AATAOTOTTGAAC	TCOTTAACTCTO	CTGATOTTA	TTTTTAATAAG	CCAAACACT	GAGGAAGACAT	AACACAGAA	GACAAACGAAA	CTAAAACCT/	ATCATO 961
	1010	1020	1030	1040	1050	1060	1070	1080	1090	1100
sequenced	O K L K I	V K K I	A K E	I D K	V L E	AT	E L Y	R C E	D P D T	L K
published	G K L K I	AOTTAAAAAAAA	TOCAAAAAA	AATTGATAAAA	OTCTTOGAAO	OTOCOACTTT	GAOCTTTAT	COTTOTGAAG	ACCCCGATAC/	ACTOAA 1061
	ATCTAAAATATCC	1120	1130	1140	1150	1160	1170	1180	1190	1200
sequenced	ATCTAAAATATCC	I II G O	лесосттоа	T T O P	C D G T	V T I	D G L	H V T D	V E D	ATGAT 1200
published	ATCTAAAATATCC	ATCAATOGACAG	TCCOCTTOG	ACCACTOOTAJ	AGACOGAAC	TGTCACCATTO	ATGOGCTOC	ATGTTACCGA	FOTCOAAGAC/	AATGAT 1161
1000000000000	1210	1220	1230	1240	1280	1260	1270	1200	1290	1300
sequenced	K F I E									
published	K F I E									
	TTOCACAAOTCOC	1920	1350	1340	1950	1360	1370	1980	1390	1400
sequenced	L A Q V A	E D D E	A V T	L V K	K V E	W K H	D T P	H L P I	T T	A G
published		AGAGOGTGATGA	TOCOOTGAC	CTTAOTTAAAA	AGOTTGAAAA	ACOTTAAACAT	GATACTOCO	AATCTTCCAA	GACADOTOO	COCAGG 1361
	1410	1420	1430	1440	1450	1460	1470	1480	1490	
sequenced	I I L	OCAOCACTTOOT	OCTCTAATC	ATCOUTOCTOC	LAGCATOGTTO	GOCACOTCOT/	ACTCAOCTA	AAAACTAGAC	COOCTTCTC	CTC 1497
published	TATCOOTATTCTTO	OCAGCACTTOOT	OCTCTAATC.	ATCOGTOCTOC	LAOCATOOTTO	OOCACOTCOT/	ACTCAOCTA	AAAACTAO		1443
	IOIL	AALG	ALI	I O A O	AHL	ARR	H R A			

Fig. 3. Alignment of the pET₃₂/LIC-SP₃₁ sequence and published nucleic acid of putative surface-anchored protein (SpaA) of *Corynebacterium pseudotuberculosis*.

The nucleotide sequence of SP31 gene showed 98% homology with putative surface-anchored protein (fimbrial subunit), SpaA gene, meanwhile SP40 show 99% homology with glyceraldehyde-3-phosphate dehydrogenase gene. The purified PCR products were successfully cloned into pET-32 Ek/LIC prokaryotic expression vector.

10 20 30 ATOGACAGCCCAGATCT000TACCGATGACGACGACGACGACGACGACGATGACGATTC0CGTAGGAATCAACG0CTTT00CCGCATC0GACGTAACTTCTACCGT0CTC 100 MDSPDLGTDDDKM R V I N R т 8 ATGACGATTCGCGTAGGAATCAACGGCTTTGGCCGCATCGGACGTAACTTCTACCGTGCTC 61 published м IRVGINGFGRI G R N 170 120 130 150 160 110 140 180 190 200 TAACCGAGGCTGGCGCTGACGTTGAGGTTGTAGCCATCAATGACCTTACGACCACACGACGACCACCACCACCACCACCTTCTGAAGACCTTATTTGGGTCG 200 L T E R G A D V E V V A I N D L T D N H T L S H L L K Y D S I L G R sequenced LL TAACCGAGCGTGGCGCTGACGTTGAGGTTGTAGCCATCAATGACCTTACGGACAACCGACGCCTTCCCACCCTTCTTAAATACGACTCTATTTGGGTCG 161 L T E R G A D V E V V A I N D L T D N H T L S H L L K Y D S I L G R ublished 210 220 230 240 250 260 270 280 290 300 sequenced correlational correlation and an analytical contraction of the second and the second a SI т v HRI 12 D . D D CCTGGGCAAGGACGTTACCTACGACGATGAGTCCATCACCGTCGATGGGCACCGCATCATCGTTACTGCAGAGCGTGATCCCCAAGGATCTGAAGTGGGAC 261 published L G K D V T Y D D E S I T V D G H R I I V T A E R D P K D L K 310 320 330 340 350 360 370 380 sequenced GTAGATATCGTTATCGAATCTACAG0GGTTCTTTACCGATGCTCATGCCGCTCAGGCACACATCGATGCTGGAGCAAAGAAGGTTATCATTTCTGCTCCTG 400 T 8. .9 T D 2 0 T D V K K V T T GTAGATATCGTTATCGAATCTACAG0GTTCTTTACCGATGCCGCTCAGGCACACATCGATGCTGGAGCAAAGAAGGTTATCATTTCTGCTCCTG 361 published Q A IESTG 7 F DA А D K K 410 420 430 440 450 460 470 480 490 CAAAGAATGAAGATGAAGATGCAACCATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTGTGTTAACCATCCAGCCACCGACCACCACCACCACCACCACCG 500 A K N E D A T F V V G V N H T D Y D P A N H H I I S N A S C T T N C sequenced published CAAAGAATGAAGATGAAGCTTTGTTGTTGTTGTTGTTGTGTGTTACCATCGAGTCAGCCAACCATCACCATCATCATCGTTCTTGCACCACCAACCG 461 K N E D A T F V V G V N H T D Y D P A N H H I I S N A ст 520 530 540 550 560 \$70 580 510 590 600 sequenced CCT00CACCTAT00CTAA00TCTT00AC0AAAA0TTT00CATT0A0AAT00TCTAAT0ACCACCOTTCAC0CTTACACT00CGATCA0C0TCTCCAC0AT 600 published ccT00cAccTAT0ACTAA00TCTT00ACGAGAAA0TTT00CATT0AGAAT00TCTAAT0ACCACCOTTCAC0CTTACACT00CGATCA0COTCCACGAT 561 V L D E K F G I E N G L M T T V H A Y T G D Q R LAPMIK 630 640 610 620 650 660 670 680 690 700 sequenced OCTCCCCACCGTGATCTGCGTCACGTGCTGCGCAGAACATTGTTCCGACCTCTACGGGTGCTGCAAAGGCTGTCGCTCTGGTTCTTCCTCAGC 700 NIVPT D L a. v L v P published GCTCCGCACCGTGATCTGCGTCGTGCACGTGCTGCGCCGCAGAACATTGTTCCGACCTCTACGGGTGCTGCAAAGGCTGTCGCTCTGGTTCTTCCTCAGC 661 LRRARAAAQNI AAK 740 710 720 730 750 760 770 780 790 800 TGAAGGGCAAACTCGATGGTTACGCGTTGCGTGTTCCTGTGATCACAGGCTCTGCAACCGATTTGACCTTCTATGCTTCCAAGGAAGTTTCTGTTGAAGC 800 sequenced ALRVP ~ ~ T T G S A T DLT KLD Y A SKE TGAAGGGCAAACTCGATGGTTACGCGTTGCGTGTTCCTGTGATCACAGGCTCTGCAACCGATTTGACCTTCTATGCTTCCAAGGAAGTTTCTGTTGAAGC 761 published ĸ GKLD YALRVPVIT GSA TDLT SKE v v **E**. 830 810 820 840 850 860 870 880 890 Τ ĸ Ε Ε Ε L LA D P D Ι 3 published IKEAAEGELK G VLA Y ΤE DP т D 31 т 5 т D 930 940 960 950 920 970 980 910 990 1000 published CACGCATCGATCTTCGACTCC00TTTGACCAAGGTTATTGGCAACCAGGTTGATGTTGTTCCT00TATGACAACGAGTG000TTACTCCAACCAACTCG 961 A S I F D S G L T K V I G N Q V K V V S W Y D N E W G Y S N Q 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 sequenced TTACCCTAACCGAGTATGTOGCGAGCGCCTTTAAACCGGGCTTCTCCCCAACCATGGCGATATCGGGTCCGACAAGCTCCGACAAGCTTGCGG 1100 T G L L L N H G D I G S E F E L R R Q A C τ. R L TTACCCTAACCGAGTATGTTGGCGAGCGCCTTTAA-996 published LTEYVGERL 1110 1120 1130 1140 CCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGC 1143 sequenced RAPPPPPLRSG C published 996

Fig. 4. Alignment of the pET32/LIC-SP40 sequence and published nucleic acid of glyceraldehyde-3-phosphate dehydrogenase of *Corynebacterium pseudotuberculosis*.

The expression of the SP31 and SP40 in the expression vector *E. coli* BL21 (DE3) showed the presence of single band of 67 kDa and 54 kDa, respectively (Figs. 5 and 6).




Fig. 5. Western immunoblotting of soluble fusion protein of recombinant SP31 after expression in *E. coli* BL21(DE3) using His.Tag Mab as primary antibody. Lane M: protein marker, lane 1: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP31 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC without insert.

Immune response

At the start of the experiment, all groups showed low level of antibody against *C. pseudotuberculosis*. Following exposure, Groups 2 and 3 showed significantly (p<0.05) high antibody level as early as week 1 (Fig. 7).




Fig. 6. Western immunoblotting of soluble fusion protein of the recombinant SP40 after expression in *E. coli* BL21(DE3) using His.Tag Mab as primary antibody. Lane M: protein marker, lane 1: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein of *E. coli* BL21 (DE3) expressing pET32/LIC-SP40 and lane 2: soluble cell protein p

Following booster, Group 3 remained insignificantly (p>0.05) higher than Group 2 until week 7 but both exposed groups showed significantly (p<0.05) higher antibody levels than the control Group 1 until week 12 (Fig. 7). At the time of challenge on week 4, both exposed groups showed significantly (p<0.05) high antibody levels than the control.

Gross pathology and bacterial isolation

Majority (14/15) of the challenged goats either exposed or non-exposed showed lesions of abscessation in the lymph nodes, except one goat of Group 2. *Corynebacterium pseudotuberculosis* was successfully isolated from all exposed goats of Group 2 and unexposed goats of Group 1. Two of the three (67%) goats of Group 2 have abscess in the lymph nodes and were positive for *C. pseudotuberculosis*.

Discussion

Generally, the efficacy of the vaccines in sheep is different when used in goat since the side effects are more intense with formation of lesions at the injection site, fever, malaise and reduced in milk production (Ribeiro et al., 2014). Nevertheless, surface proteins are believed to play important role in host-pathogen interaction and have shown to be highly immunogenic when used for vaccine preparation (Pacheco et al., 2011). In this study, we showed that the 31 kDa and 40 kDa surface proteins were good antigens when they cross-reacted with the hyperimmune serum against whole cell С. pseudotuberculosis.

The recombinant cells that carry the 31 kDa surface protein were recognized as putative surface-anchored protein (fimbrial subunit) SpaA gene. This putative surface-anchored protein contains 1442 nucleotides that encodes 480 amino acids and could be detected in pathogenic *Corynebacterium*. The gene is present in the pili of pathogenic *Corynebacterium* sp. that assists in attachment of the bacterium to the host cell (Rogers *et al.*, 2011). Furthermore, it was reported that the adhesive pili of *C. pseudotuberculosis* FRC41 consisted of major pilin subunit SpaA, suggesting the SpaA as a potential virulence factor (Trost *et al.*, 2010). Protein expression of the recombinant cells revealed the presence of single band of approximately 68 kDa corresponding to the recombinant fusion protein of 17 kDa tagged protein and 51 kDa recombinant SpaA.

Recombinant cells carrying the 40 kDa protein consisted of 996 bp nucleotides that encodes 332 amino acid. This recombinant protein encoded glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, a glycolytic enzyme that involves in glycolytic pathway (Oliveira *et al.*, 2012). The GAPDH is one of the newly identified extracellular proteins that can be a target in prevention against CLA as it is found in the surface protein of various pathogens with an ability to modulate the host immune system during infection (Silva *et al.*, 2013). The protein expression revealed presence of single band of 53 kDa, which corresponded to 36 kDa of GAPDH and 17 kDa fusion proteins.




Fig. 7. Serum IgG levels of goats against *C. pseudotuberculosis* following exposures to inactivated recombinant cells. Generally, the exposed goats of Groups 2 and 3 showed significantly (p<0.05) high antibody levels than the control Group 1.

Following development of recombinant cells, they were used to determine the ability to enhance immunity and prevent infection in goats.

Exposures to the recombinant cells increased the IgG levels as early as week 1 post-vaccination and remained significantly high following booster dose until the end of the 12-week study period. However, following challenge with live *C. pseudotuberculosis*, almost all exposed and unexposed goats developed abscessation in the lymph nodes while *C. pseudotuberculosis* was successfully isolated from all groups. These suggest that the recombinant cells carrying the surface protein are able to enhance humoral immune response but not protective against infection by live *C. pseudotuberculosis*. Similarly, vaccinating alpacas with cell wall components of *C. pseudotuberculosis* resulted in a robust humoral

reaction against *C. pseudotuberculosis* but gave no protection with the presence of abscess in internal and regional lymph nodes (Braga, 2007). It is suggested that effective vaccination against caseous lymphadenitis requires stimulation of the host reticuloendothelial system since *C. pseudotuberculosis* is an intracellular organism (Izgur *et al.*, 2010).

Furthermore, most vaccines that are based on recombinant protein present weak or poor immunogenicity when given alone thus require an adjuvant to elicit the protective and long lasting immune response (Nascimento and Leite, 2012).

References

Braga WU. 2007. Protection in alpacas against *Corynebacterium pseudotuberculosis* using different bacterial components. Veterinary Microbiology **119**, 297-303.

Cameron CM, Maria M. 1971. Mechanism of immunity to *Corynebacterium pseudotuberculosis* (Buchanan, 1911) in mice using inactivated vaccine. Journal of Veterinary Research **38(2)**, 73-82.

Centikaya B, Karahan M, Atil E, Kalin R, De Baere T, Vaneechoutte M. 2002. Identification of *Corynebacterium pseudotuberculosis* isolates from sheep and goats by PCR. Veterinary Microbiology **88**, 75-83.

Desvaux M, Dumas E, Chafsey I, Hebraud M. 2006. Protein cell surface display in Gram-positive bacteria: from single protein to macromolecular protein structure. Federation of European Microbiology Society **256**, 1-15.

Dorella FA, Pacheco LGC, Oliviera SC, Miyoshi A, Azevedo V. 2006. *Corynebacterium pseudotuberculosis*: Microbiology, biochemical properties, pathogenesis and molecular studies of virulence. Veterinary Research **37**, 201-218.

Fontaine MC, Baird GC. 2008. Caseous lymphadenitis. Small Ruminant Research **76**, 42-48.

Guimarães AS, Carmo FB, Pauletti RB, Seyffert N, RibeiroD, Lage AP, Heinemann MB, Miyoshi A, Azevedo V, Gouveia AMG. 2011. Caseous lymphadenitis: Epidemiology, diagnosis and control. Institute of Integrative Omics and Applied Biotechnology Journal **2**, 33-43.

Hoelzle LE, Scherrer T, Muntwyler J, Wittenbrink MM, Philipp W, Hoelzle K. 2013. Differences in the antigen structures of *Corynebacterium pseudotuberculosis* and the induced humoral immune response in sheep and goats. Veterinary Microbiology **164**, 359-365.

Izgur M, Akan M, Ilhan Z, Yazicioglu N. 2010. Studies on vaccine development for ovine caseous lymphadenitis. Ankara Universiti Veteriner Fakultesi Dergisi **57**, 161-165. Literak I, Horvathova A, Jahnova M, Rychlik I, Skalka B. 1999. Phenotype and genotype characteristics of the Slovak and Czech *Corynebacterium pseudotuberculosis* strains isolated from sheep and goats. Small Ruminant Research **32**, 107-111.

Nascimento IP, Leite LCC. 2012. Recombinant vaccines and development of new vaccine strategies. Brazillian Journal of Medicine and Biological Research **45**, 1102-1111.

Nur-Nazifah M, Sabri MY, Siti-Zahrah A. 2014. Development and efficacy of feed-based recombinant vaccine encoding the cell wall surface anchor family protein of *Streptococcus agalactiae* against streptococcosis in *Oreochromis* sp. Fish and Shellfish Immunology **37**, 193-200.

Oliveira L, Madureira P, Andrade EB, Bouaboud A, Morello E, Ferreira P, Poyart C, Trieu-Cuot P, Dramsi S. 2012. Group B Streptococcus GAPDH is released upon cell lysis, associate with bacterial surface, and induces apoptosis in murine macrophages. Plos –one 7(1), e29963.

Pacheco LGC, Slade SE, Seyffert N, Santos A R, Castro TLP, Silva WM, Santos AV, Santos SG, Farias LM, Carvalho MAR, Pimenta AMC, Meyer R, Silva A, Scrivens JH, Oliveira SC, Miyoshi A, Dowson CG, Azevedo V. 2011. A combined approach for comparative exoproteome analysis of *Corynebacterium pseudotuberculosis*. BMC Microbiology 11, 12-25.

Paule BJA, Azevedo V, Regis LF, Carminati R, Bahia CR, Vale VLC, Moura-Costa LF, Freire SM, Nascimento I, Schaer R, Goes AM, Meyer
R. 2003. Experimental *Corynebacterium pseudotuberculosis* primary infection in goats: Kinetics of IgG and interferon-g production, IgG avidity and antigen recognition by western blotting. Veterinary Immunology and Immunopathology 96, 129-139.

Paule BJA, Meyer R, Moura-Costa LF, Bahia RC, Carminati R, Regis LF, Vale VLC, Freire **SM**, Nascimento I, Schaer R, Azevedo V. 2004. Three-phase partitioning as an efficient method for extraction/concentration of immunoreactive excreted–secreted proteins of *Corynebacterium pseudotuberculosis*. Protein Extraction and Purification **34**, 311-316.

Ribeiro D, Rocha FS, Leite KMC, Soares SC, Silva A, Portela RWD, Meyer R, Miyoshi A, Oliveira SC, Azevedo V, Dorella FA. 2014. An iron-acquisition-deficient mutant of *Corynebacterium pseudotuberculosis* efficiently protects mice against challenge. Veterinary Research 45, 28-33.

Rogers EA, Das A, Ton-That H. 2011. Adhesion by pathogenic Corynebacteria. Advances in Experimental Medicine and Biology **715**, 91-103.

Sabri MY, Zamri-Saad M, Mutalib AR, Israf DA, Muniandy N. 2000. Efficacy of an outer membrane protein of *Pasteurella haemolytica* A2, A7 or A9-enriched vaccine against intratracheal challenge exposure in sheep. Veterinary Microbiology **73**, 13-23.

Schneewind O, Missiakas D. 2014. Sec-secretion and sortase-mediated anchoring of proteins in Grampositive bacteria. Biochimica et Biophysica Acta 1843, 1687-1697. Silva WM, Seyffert N, Santos AV, Castro TLP, Pacheco LGC, Santos AR, Ciprandi A, Dorella FA, Andrade HM, Barh D, Pimenta AMC, Silva A, Miyoshi A, Azevedo V. 2013. Identification of 11 new exoproteins in *Corynebacterium pseudotuberculosis* by comparative analysis of exoproteome. Microbial Pathogenesis **61-62**, 37-42.

Simmons CP, Dunstan SJ, Tachedjian M, Krywult J, Hodgson ALM, Strugnell RA. 1998. Vaccine potential of attenuated mutants of *Corynebacterium pseudotuberculosis* in sheep. Infection and Immunity **66**, 474-479.

Trost E, Ott L, Schneider J, Schroder J, Sebastian J, Goesmann A, Husemann P, Stoyes J, Dorella FA, Rochas FS, Soares SC, D'Afonseca V, Miyoshi A, Ruiz J, Silvas A, Azevedo V, Burkovski A, Guiso N, Join-Lambert OF, Kayal S, Tauch A. 2010. The complete genome sequence of *Corynebacterium pseudotuberculosis* FRC41 isolated from a 12-yearold girl with necrotizing lymphadenitis reveals insights into gene regulatory networks contributing to virulence. BMC Genomics **11**, 728-748.